Castle Biosciences Inc
$ 30.47
0.23%
06 Aug - close price
- Market Cap 928,705,000 USD
- Current Price $ 30.47
- High / Low $ 30.75 / 29.50
- Stock P/E N/A
- Book Value 15.41
- EPS -0.62
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.04 %
- 52 Week High 44.28
- 52 Week Low 17.72
About
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.
Analyst Target Price
$44.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-06 | 2026-02-26 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-02-27 | 2024-11-04 | 2024-08-05 | 2024-05-02 | 2024-02-28 | 2023-11-02 |
| Reported EPS | -0.07 | -0.49 | -0.08 | -0.02 | 0.15 | -0.9 | 0.32 | 0.08 | 0.31 | -0.09 | -0.1 | -0.26 |
| Estimated EPS | -0.44 | -0.49 | -0.23 | -0.51 | -0.5 | -0.07 | 0.04 | 0.01 | -0.24 | -0.31 | -0.54 | -0.73 |
| Surprise | 0.37 | 0 | 0.15 | 0.49 | 0.65 | -0.83 | 0.28 | 0.07 | 0.55 | 0.22 | 0.44 | 0.47 |
| Surprise Percentage | 84.0909% | 0% | 65.2174% | 96.0784% | 130% | -1185.7143% | 700% | 700% | 229.1667% | 70.9677% | 81.4815% | 64.3836% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CSTL
2026-08-07 07:09:25
Castle Biosciences insider Derek Maetzold sold 2,546 shares of the company's stock for approximately $78,111, reducing his position by 10.6%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently surpassed quarterly revenue and EPS expectations, and while analyst sentiment is generally positive, several insiders have sold shares, though these sales were pre-planned.
2026-08-07 00:41:00
Castle Biosciences insider Derek Maetzold sold 20,356 shares of the company's stock for over $633,000, reducing his ownership by nearly half. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company recently reported better-than-expected quarterly results, and analysts maintain a "Moderate Buy" rating with a consensus price target of $42.00.
2026-08-06 23:41:00
Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 1,301 shares of the company's stock for approximately $49,945, reducing his position by 1.65%. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Despite insider sales, Castle Biosciences' recent quarterly results exceeded expectations with higher revenue and a narrower per-share loss, and Wall Street maintains a "Moderate Buy" consensus with an average price target of $42.00.
2026-08-05 13:42:37
Tobin Juvenal, Chief Commercial Officer of Castle Biosciences (CSTL), sold 19,040 shares of the company's stock for approximately $556,158. This transaction is part of a broader trend of insider selling at Castle Biosciences, with 50 insider sells and zero buys over the past year. Despite the insider selling, GuruFocus's valuation model suggests the stock is "Fairly Valued" at a price-to-GF-Value ratio of 0.99, and some institutional investors are adding to their positions, indicating a divergent opinion on the company's prospects.
2026-08-02 06:41:19
Frank Stokes of Castle Biosciences Inc. has been recognized as an honoree for the Houston Business Journal's 2026 CFO Awards. The article highlights Stokes as one of several distinguished individuals acknowledged for their financial leadership. Other honorees include Frank Wilson IV, Ebru Akyildiz, Stephanie Alvarez, and Chinelo Aralu.
2026-08-01 23:40:06
Castle Biosciences, Inc. (CSTL) has seen its average 12-month price target raised to $43.56 from $42.78 by 9 analysts, implying a potential upside of approximately 63% from its July 30 closing price. The consensus rating for the stock remains a "Buy" across all covering analysts.
